March 21st Highlights

  • Medical Cannabis in Peru - With a population of 33 million and the fifth-largest economy in Latin America, Peru’s medical cannabis market is estimated to be worth US$99 million (Prohibition Partners). With a regulatory environment similar to Colombia, Peru is an early mover in Latin America and has established a legal framework for producing, importing, and selling cannabis products for medical use. Consequently, the Peruvian market is advancing rapidly and has the potential to register diverse cannabis-based products. In 2020, MediPharm Labs entered into the growing Latin American cannabis market with Cann Farm Peru
  • Cannabis increase during Pandemic - A group of researchers at the Toronto-based Centre for Addiction and Mental Health (CAMH) recently conducted a study that found “just over half (52 percent) of those who had consumed cannabis in the previous week said that they were consuming it more than they were before the pandemic.” The study was published in the American Society of Addiction Medicine and consisted of three surveys conducted in May and June of 2020. Survey participants from across Canada were selected from a pool of more than a million people maintained by the research technology and consumer data collection company Delvinia. This data is consistent with the increase in cannabis approvals in Australia through lockdown periods. Reference Material

Medical cannabis offers help for child conditions, but cost out of reach for many

Medical cannabis studies ramp up, offering hope to some opioid users

A German doctor at the forefront of medical cannabis

Cannim Australia unveils debut product

CSIRO looks to get into medicinal cannabis to take advantage of US$44bn market

VPCL completes cannabis company buyout, becomes Health House International

Green Party pushing for cross-party decriminalisation bill that would skip members' ballot

ECS completes acquisition of Murray Meds

Big changes for Tasmania’s Controlled Access Scheme

Tilray receives approvals to expand medical cannabis products in New Zealand

CannPal Animal Therapeutics concludes trade on ASX on AusCann Group acquisition